MCU and breast carcinoma: Similarly, in breast cancer, the downregulation of miR-340 is correlated with increased MCU expression in highly metastatic cells, while MCU targeting by miR-340 blocks the metabolic shift from OXPHOS to aerobic glycolysis that would otherwise favour cell migration and invasiveness77.